OptiNose

OptiNose — Q1 2019 Earnings Presentation

17 slides from OptiNose's earnings presentation, May 9, 2019

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 9, 2019

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Optinose Key Priorities

    Optinose Key Priorities Continue to drive XHANCE® prescription growth Advance our XHANCE clinical program for a follow-on indication for the treatment of Chronic Sinusitis Support our commercial and development objectives through efficient use of capital ■ $171 Million of cash as of March 31, 2019 3

  4. Slide 4: XHANCE Launch Update

    XHANCE Launch Update optinose_

  5. Slide 5: Key Levers to Continue to Drive XHANCE Growth

    Key Levers to Continue to Drive XHANCE Growth Continued Execution of Strategy (Defined Appropriate Patient Type, Enhanced Efficacy Message & Affordability Program) Sales Force Expansion 7-Day Samples Increase Payer Coverage Direct to Consumer Pilot 5

  6. Slide 6: Deployed Territory Managers to New Territories; Promoting XHANCE in 100 Territories

    Deployed Territory Managers to New Territories in April and now Promote XHANCE in 100 Territories Total Albany, NY XHANCE® Sales Territories Albuquerque, NM NEW Baltimore, MD Boston, MA Charleston, SC Columbia, SC Detroit (South), MI Dothan, Al Fort Wayne, IN Grand Rapids, MI Greenville, SC Huntingt

  7. Slide 7: XHANCE Prescription Volume Grew 59% in Q1 2019 versus Q4

    XHANCE Prescription Volume Grew 59% in Q1 2019 versus Q4 2018 Continued growth in Q1 2019 driven by promotional materials and patient affordability program rolled out in August/September 2018 XHANCE TRx +59% 25,000 22,490 +50% 20,000 15,000 14,106 9,427 10,000 8,611 5,000 0 Q2 '18 Q3 '18 Q4 '18 Q1 '

  8. Slide 8: XHANCE Prescription Volume Grew 15% for Most Recent Week Period

    XHANCE Prescription Volume Grew 15% for the most recent 4 Week Period Ended April 26, 2019 Early Q2 2019 Prescription Trends Aligned with Q4 2018 and Q1 2019 Growth Rates XHANCE TRx +15% 10,000 9,515 9,000 8,298 8,000 7,000 6,000 5,000 4 Weeks ended 4 Weeks ended 3/29/19 4/26/19 Market TRx for Intra

  9. Slide 9: Q1 2019 Financial Update

    Q1 2019 Financial Update optinose_

  10. Slide 10: Financial Review – First Quarter 2019

    Financial Review – First Quarter 2019 Q1 2019 Net Product Revenues and Average Net Product Revenues per TRx ($M ) Net Product Revenues $4.0 . Net product revenues $3.0 increased 32% in Q1 2019 versus Q4 2018 $1.9 . Average net product revenues of $177 per TRx in $1.3 Q1 2019 − Slightly higher than e

  11. Slide 11: Financial Review – 2019 Financial Guidance

    Financial Review – 2019 Financial Guidance . Full Year 2019 Operating Expenses (GAAP) expected to be in the range of $135 - $142 million • $10 - $12 million of which represents stock-based compensation • First Quarter 2019 Operating Expenses of $30.9 million . Full Year 2019 average net revenue per

  12. Slide 12: Pipeline Update

    Pipeline Update optinose_

  13. Slide 13: XHANCE Chronic Sinusitis Indication (sNDA)

    XHANCE Chronic Sinusitis Indication (sNDA) Study 3205 - ClinicalTrials.gov Identifier: NCT03781804 . 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study . First patient enrolled in Q4 2018 . Estimated enrollment: 378 patients . Focused on successful execution of s

  14. Slide 14: Closing Remarks

    Closing Remarks optinose_

  15. Slide 15: Building a leading ENT/Allergy Specialty Company

    Building a leading ENT/Allergy Specialty Company XHANCE® represents a significant opportunity in the ENT/Allergy market with the current indication Potential for CS indication provides pipeline value Future business development expected to focus on leveraging ENT/Allergy infrastructure and expertise

  16. Slide 16: Investor Relations

    Investor Relations – NASDAQ: OPTN At 31 March 2019: Analyst Coverage1 – $171 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.3 million common shares o/s – 9.6 million options & warrants o/s Jefferies: David Steinberg Cantor Fitzgerald: Brandon Folkes Optinose Investor Contact Jo

  17. Slide 17: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 9, 2019

OptiNose — Q1 2019 Earnings Presentation on 6ix